Ideaya Biosciences (IDYA) announced the clearance of an investigational new drug application with the FDA for the initiation of a Phase 1 clinical trial to evaluate IDE034, a bispecific B7H3/PTK7 TOP1 antibody-drug conjugate. Ideaya expects to begin enrolling the study in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck and ovarian/gynecological cancers. Based on the Human Protein Atlas database, B7H3/PTK7 has been reported to be co-expressed in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- Ideaya Biosciences initiated with a Buy at Truist
- Ideaya Biosciences price target raised to $46 from $44 at Mizuho
- IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
- IDEAYA Biosciences Reports Strong Q3 2025 Results